ABSI'HACT. Multiple acyl-CoA dehydrogenation disorders result from generalized defects in intramitochondrial acyl-CoA dehydrogenation. Fibroblasts from a riboflavinresponsive multiple acyl-CoA dehydrogenation disorder patient catabolized I4C-butyrate, -octanoate, and -leucine normally after culture in riboflavin-supplemented medium (2 mg/L). After culture in riboflavin-depleted medium (51.4 pg/L), his cells oxidized the same substrates poorly at 20 to 33% of control ( p < 0.05). Patient cells incubated in a wide range of ~-[2-'~C]riboflavin concentrations (3, 31.4 , and 100 pg/L) synthesized I4C-flavin mononucleotide and I4C-flavin adenine dinucleotide (FAD) normally and had normal cytosolic I4C-flavin mononucleotide and I4C-FAD contents, which argues against defects in cellular riboflavin uptake and conversion to flavin mononucleotide and FAD. After culture in 31.4 pg I4C-riboflavin/L for 2 wk, I4C-FAD specific radioactivities plateaued and were similar in patient and control cells. However, culturing these uniformly labeled cells in riboflavin-depleted medium for 2 \r k lowered the patient's cellular I4C-FAD content to only 23% of control levels. Similarly, after incubation in low I4C-riboflavin concentrations (4.4 pg/L), the patient's mitochondrial I4C-FAD content was only 51% of control after I h and 29% of control a t 4 h. After a 4-h incubation in a high physiologic concentration of I4C-riboflavin (31.4 pg/L), which raised the patient's cellular I4C-FAD levels 3-to Cfold, his mitochondrial I4C-FAD content rose to normal; control values did not change. We also investigated possible defective FAD binding to flavoenzymes essential for acyl-CoA dehydrogenation. Medium-chain acyl-CoA dehydrogenase activities did not fall significantly in either patient or control mitochondria from cells cultured in riboflavin-depleted medium. However, after culture in riboflavin-depleted medium, the patient's electron transfer flavoprotein activity fell to 59% of control in mitochondrial preparations, which is compatible with decreased matrix FAD content. We postulate that defective maintenance of mitochondrial FAD levels explains this patient's riboflavin-responsive multiple acyl-CoA dehydrogenation disorder phenotype. The MAD are a group of human metabolic diseases affecting amino acid and fatty acid catabolism (I) . Recognized variants include glutaric aciduria type 11 or severe MAD (MADS). ethylmalonic aciduria or mild MAD (MAD:M). and riboflavin-responsive MAD (2-4). Most MAD:S patients present at birth with severe hypoglycemia. metabolic acidosis without ketosis. and a complex organic aciduria consisting of many fatty acid-and amino acid-derived metabolites. notably lactic. glutaric. ethylmalonic. adipic, and branched-chain organic acids: most die in the neonatal period (5) . MAD:M patients usually present with less severe and varying clinical symptoms. including episodic hypoglycemia and acidosis. at ages ranging from infancy to early adulthood (3. 6): prominent urinary metabolites include ethylmalonic and adipic acids. similar to those found in MADS patients.
In these disorders. dehydrogenation of multiple acyl-CoA is blocked due to defective electron transport from the acyl-CoA to ubiquinone (CoQlo) of the electron transport chain ( 1. 5). This sequence of mitochondrial oxidation-reduction reactions is mediated by a group of FAD-requiring enzymes: ADH. ETF. and ETF:ubiquinone oxidoreductase: all these enzymes ionically bind their cofactor FAD very tightly (k, 5 2.4 pM: 1. 7, 8). In general.
MAD patients display normal or near normal ADH activities (7) (8) (9) . MAD:S patients have displayed very low activities ofeither ETF or ETF:ubiquinone oxidoreductase. whereas M AD:M patients have moderately deficient activities of one of these two enzymes (7. 8) .
In contrast. the biochemical defects underlying the riboflavinresponsive MAD have not been identified. The first patient with this variant was described by Gregersen ct 01. (4) ["C(U)]palmitate at 50% of control levels (4). fibroblast ADH activities. FMN. and FAD synthesis were normal after culture in supraphysiologic riboflavin concentrations (I) . These observations tended to exclude a defect in cellular riboflavin uptake, FMN and/or FAD synthesis, or altered ADH apoenzymes as the primary abnormality in this patient. However, culture in vitamin-depleted medium is often necessary to demonstrate the enzymatic defect in fibroblasts from patients with vitamin responsive disorders. as culture in supraphysiologic vitamin concentrations can correct the metabolic block in virro (lo).
In preliminary studies. this patient's fibroblasts catabolized 14 C-labeled octanoate and leucine normally after culture in riboflavin-supplemented media. However, after culture in riboflavindepleted media. his cells oxidized the same substrates much more poorly. confirming the riboflavin responsiveness of his metabolic defect in fibroblasts ( I I). We report here related cell oxidation studies in detail, as well as data arguing against defective FMN or FAD synthesis or altered FAD binding to mutant ADH or ETF apoenzymes. We suggest that defective maintenance of mitochondrial FAD levels explains his riboflavin-responsive phenotype.
MATERIALS A N D METHODS
Substrates for intact cell oxidation studies were [I - Skin fibroblasts were obtained from the patient (courtesy of Dr. N. Gregersen) and from five normal male infants. Cells were cultured in Eagle's MEM supplemented with 5% FCS, 2 mM glutamine, 140 pM penicillin. and 86 pM streptomycin. Medium was changed every week and fibroblasts were subcultured 1:4 every 2 wk. Fibroblasts of passage 8-18 were used in all assays.
Unless otherwise stated. patient and control fibroblasts were subcultured 2 wk before the indicated assays into riboflavin-free MEM (KC Biologicals, Kansas City, KS) supplemented with 5% or 10% Nu-Serum (Collaborative Research. Cambridge, MA). yielding final concentrations of 51.4 or 52.8 pg riboflavin/L, respectively. Two mg riboflavin/L was added to half the flasks (designated riboflavin-supplemented medium); no further riboflavin was added to the remaining flasks (designated riboflavindepleted medium). One wk before assay, cells were fed with either riboflavin-depleted or riboflavin-supplemented medium containing 5% Nu-serum. In all experiments involving added riboflavin, cells were incubated in total darkness. Catabolism of I4C-labeled substrates and 'H-palmitates were assayed in intact cells using the methods previously described (6, 7, 9) . After culture in riboflavin-depleted media for 2 wk and the 3-h oxidation experiments, cell viability was greater than 95% in both patient and control cells. as measured by trypan blue exclusion (data available on request).
Cellular riboflavin uptake and conversion to FMN and FAD were measured in whole cells by modifying Christensen's procedure ( 1 3): all manipulations were performed in reduced light. Fibroblasts from patient and control cells were grown to confluence in MEM supplemented with 5% FCS. The medium was then replaced with riboflavin-free MEM without FCS containing "C-riboflavin at the indicated concentrations; the flasks were incubated for the indicated intervals at 37°C. Cells were harvested by trypsinization, centrifuged at 700 x g for 10 min, resuspended, and sonicated into 0.3 mL 5% aq Na2HP04, 0.6 mL MeOH. and 60 pL carrier solution (0.06 mg each riboflavin, FMN, and FAD). MeOH precipitates proteins, releases FMN and FAD from proteins, and inactivates FMN and FAD hydrolyzing phosphatases active in cell homogenates (14) (15) (16) ). An aliquot was removed for protein determination and the remainder was incubated overnight at 4°C and centrifuged at 12 000 x g for 30 min: 25 pL of supernatants were used for separation of riboflavin, FMN. and FAD by thin-layer chromatography on Redi-coat silica gel glass plates (Supelco, Inc., Bellefonte. PA) with a solvent of 5% aq Na2HP04, a running time of 40 min, and a 15-cm front. Characteristic Rf values for this system were: riboflavin. 0.32: FMN, 0.45; and FAD, 0.61 (14) . FMN and FAD spots were visualized under a U V lamp. scraped and collected into 10 mL of Scintiverse I (Fisher Scientific, Fairlawn, NJ). and counted in a Beckman scintillation counter (model LS8 100: St. Louis. MO): recoveries of both from the plates were 75-80%.
To uniformly radiolabel cellular flavin cofactor pools. patient and control cells were incubated in riboflavin-depleted medium for 24 h and then cultured in medium containing 31.4 pg I4C-riboflavin/L for up to 3 wk. The cells were then cultured in riboflavin-depleted medium for 2 additional wk. Cellular I4C-flavin contents were quantitated as described above at 2, 5, 8. 14, and 2 1 d during the uniform labeling phase and at 0. 1, 4. 7. and 14 d during the depletion phase.
Mitochondrial I4C-FMN and -FAD contents were also measured in patient and control cells grown in riboflavin-depleted medium for 2 wk. These flasks were then incubated in riboflavindepleted MEM with 4.4 pg I4C-riboflavin/L for 1 and 4 h or with 3 1.4 pg I4C-riboflavin/L for 4 h at 37°C. Cells were harvested by trypsinization (0.3-0.4 g wet weight/culture), and mitochondria were isolated as described previously, except that digitonin treatment was omitted (7, 17) . This method yields fibroblast mitochondria purified 14-fold over cell homogenates and removes 80% of contaminating lysosomes (17) . Mitochondrial pellets were suspended in 75 pL 5% aq Na2HP04 and an aliquot was assayed for glutamate dehydrogenase as described earlier (18) . Proteins were precipitated with 0.15 mL MeOH and I4C-FMN and -FAD quantitated as described in the preceding paragraph.
In cells incubated with 4.4 fig 14C-riboflavin/L for 4 h, cystosolic fractions obtained during mitochondrial isolation were analyzed for I4C-FMN and -FAD content. The volume of each fraction was measured and an aliquot was removed for protein determination. To each volume of cytosolic fraction, 2 volumes MeOH and 0.2 volumes carrier solution (0.1 mg each/mL riboflavin. FMN, and FAD) were added and the mixture was incubated in the dark at 4°C overnight. The precipitate was pelleted by centrifugation (12 000 x g for 30 min) and the supernatant evaporated to dryness on a rotary evaporator R-1 10 (Buchi/ Brinkmann Instruments, Slawil, Switzerland). The residue was redissolved in 3 mL Hz0 and applied to a G-10 Sephadex column ( I x 35 cm), and eluted with H 2 0 at a flow rate of 3 mL/min. I4C-FMN and -FAD coeluted first, followed by riboflavin. Fractions were visualized with a UV lamp and aliquots of the I4C-FMN and -FAD fractions were counted; FMN and FAD recoveries were 75-80%.
MCADH activity was measured in cell and mitochondrial sonic supernatants from patient and control fibroblasts using previously described tritium release and dye reduction assays. respectively (7) . Concentrations of octanoyl-CoA and electron transfer agents. phenazine methosulfate and ETF, respectively. were chosen to maximize activities in these two assay systems (7, 17) . The tritium release assay for the ADH is subject to a tritium isotope effect of 2 to 5 (1 7: other data not shown). which artifactually lowers cell supernatant activities relative to those predicted from the mitochondrial dye reduction assay. Supernatant aliquots from patient and control cells grown in ribofla-RIBOFLAVIN-RESPONSIVE MAD vin-depleted media were preincubated with FAD (20 pM) for 5 min before assay and MCADH activity was then measured. ETF activity was measured in mitochondrial sonic supernatants from patient and control cells grown in riboflavin-supplemented and -depleted media using the optimized dye reduction method previously described (7) .
Protein was determined by a fluorometric method (19) . The estimate of variance used is the SEM. All p values given were calculated by t test, are two-tailed, and compare patient to appropriate control values, unless stated otherwise.
RESULTS
We have used I4C-and 3H-substrate oxidation assays to quantitate the metabolic defect in other MAD patients (6, 9) . After culture in standard media (Eagle's MEM) containing 0.1 mg riboflavin/L, the patient's fibroblasts oxidized Because culture in riboflavin-depleted media unmasked the patient's metabolic defect, we measured cellular riboflavin uptake and conversion to FMN and FAD in patient and control fibroblasts incubated with 3, 3 1.4, and 100 pg I4C-riboflavin/L, concentrations ranging from 10 to 300% of mean plasma flavin levels in man (20) . The patient's cells synthesized I4C-FMN and -FAD normally after 4 h in all three concentrations and after I and 10 h in 3 1.4 pg I4C-riboflavin/L (Table 2) . In all cells, incubation in 3 1.4 pg 14C-riboflavin/L raised cellular I4C-flavin contents 3-to 5-fold over those found after culture in 3 pg IACriboflavin/L. However, incubation with 100 pg '4C-riboflavin/L did not further raise cellular I4C-flavin levels, suggesting that 3 1.4 pg/L was saturating for cellular riboflavin uptake and flavin cofactor synthesis. In other experiments, we also measured cytoplasmic levels of I4C-flavins in cells grown in riboflavin-depleted media and incubated with low I4C-riboflavin (4.4 pg/L) for 4 h: the sum of I4C-FMN and -FAD was similar in both control and patient cytoplasm (3.6 k 0.43 and 2.8 f 0.37 pmol/ mg protein, respectively; n = 3, p > 0.4). further arguing against defective FMN and FAD synthesis in the patient's cells.
Although these short-term radiolabeling experiments demonstrated no defects in I4C-FMN and -FAD synthesis in the patient's cells, the amounts of I4C-flavins synthesized may not accurately reflect the steady state sizes of cellular flavin cofactor pools. For this reason, we uniformly labeled cellular I4C-flavins by culturing patient and control cells in 31.4 pg I4C-riboflavin/L for 3 wk. After 2 wk, cellular I4C-FMN and -FAD specific radioactivities had plateaued and did not increase further at 3 wk (Table 3: other data not shown). Interestingly. control I4C-FAD specific radioactivities after 10 h of culture were 47% of those found after 2 wk of uniform labeling (2 1.2 and 45.0 pmol/mg/protein. respectively: n r 3). suggesting that a substantial proportion of cellular flavin pools turn over rapidly. These uniformly labeled cells were then cultured in riboflavin-depleted medium for 2 wk, with intact cell I4C-flavin levels determined at intervals during the depletion phase. After 4, 7, and 14 d of riboflavin depletion. patient I4C-FAD cell contents were 48. 37, and 23% of control. respectively (one-tail p 5 0.03 for all). Patient I4C-FMN levels were 15 and 28% of control after 7 and 14 d of depletion.
respectively (one-tail p < 0.05: data available on request). Thus, flavin cofactor homeostasis appears profoundly altered in this patient's cells when they are cultured under conditions of riboflavin deprivation. Because most cell flavins are contained in the mitochondria. we then measured mitochondria1 I4C-FMN and -FAD levels in cells incubated with 14C-riboflavin at varying concentrations and intervals. After incubations in 4.4 pg '4C-riboflavin/L. the patient's mitochondrial I4C-FMN contents rose between 1 and 4 h but remained lower than control at both times (44 and 54% of control, respectively: Table 4 ). After incubation with 4.4 pg I4C-riboflavin/L. the patient's I4C-FAD content was 5 1 % of control at I h ( p < 0.05). After 4 h, control mitochondrial I4C-FAD content had increased significantly ( p = 0.05 compared with 1-h control). whereas the patient's I4C-FAD content did not change and was 29% of control ( p < 0.05).
After 4 h of incubation with 3 1.4 pg '4C-riboflavin/L, a high physiologic concentration. control and patient cellular I4C-FAD contents had increased to comparable high values (Table 2 ) and the patient's mitochondria then contained normal amounts of I4C-FAD (Table 4) . Control mitochondrial I4C-FAD content was similar to that found after culture in low riboflavin concentrations. whereas the patient's I4C-FAD content had risen significantly ( p < 0.01). Analogously. patient mitochondrial I4C-FMN content rose after incubation in high I4C-riboflavin for 4 h. whereas control I4C-FMN content did not change. These observations suggest that control mitochondrial I4C-flavin contents reached maximal values after incubation for 4 h in low extracellular I4C-riboflavin concentrations (4.4 pg/L). whereas the patient's cells required incubation in 7-fold higher extracellular concentrations to attain similar levels. Activity of glutamate dehydrogenase, a mitochondrial matrix marker enzyme, was similar in both control and patient mitochondrial preparations (2.1 2 0.28 and 1.9 2 0.42 nmol/mg proteinlmin. respectively: p > 0.6). suggesting that the observed differences in flavin content did not result from differing purity of mitochondria from control and patient's cells.
The finding that riboflavin depletion profoundly decreased 14C-octanoate oxidation in patient fibroblasts. but not in control cells, could be explained by aberrant FAD binding to a mutant MCADH. a rate-limiting enzyme of @-oxidation catalyzing the initial dehydrogenation step of Ch-C12 fatty acyl-CoA (1). After culture in riboflavin-supplemented media. patient MCADH activity was 69% of control in cell sonic supernatants when measured with a tritium release assay ( p > 0.2: data available on request). After culture in riboflavin-depleted media. both control and patient MCADH activities fell dramatically and remained identical. When both control and patient cell sonic supernatants were preincubated with 20 pM FAD before assay. no restoration of activity was seen, suggesting loss of MCADH apoenzyme Because ETF catalyzes the initial step in electron transfer from the six reduced ADH to the electron transport chain, a mutant ETF apoenzyme with decreased affinity for FAD could explain this patient's riboflavin-responsive phenotype. However, after culture in riboflavin-depleted media, ETF activities were identical in both control and patient cell sonic supernatants ( p > 0.8; data available on request). Because reconstitution of ETF holoenzyme from cystolic FAD and mitochondrial matrix apoenzyme could explain these latter results, we also assayed ETF in mitochondrial matrix fractions. In riboflavin-supplemented cells, the patient's ETF activity was 75% of control (Table 5 ; p > 0.2); however, after culture in riboflavin-depleted medium, the patient's ETF activity fell to 59% of control (one-tail p < 0.05), compatible with low mitochondrial FAD content lowering ETF activity. Preincubation with 20 pM FAD raised the patient's ETF activity to 76% of control ( p > 0.2). comparable to the values in riboflavin-supplemented cells and consistent with reconstitution of active ETF holoenzyme.
DISCUSSION
This patient excreted metabolites consistent with the generalized defect in mitochondrial acyl-CoA dehydrogenation characteristic of the MAD (1. 5). His marked clinical and biochemical responses to supraphysiologic riboflavin doses suggested that he was a riboflavin-responsive MAD variant (4). Because MAD fibroblasts oxidize I4C-labeled fatty and amino acids poorly, cell oxidation studies were performed. After culture in media containing routine or high riboflavin concentrations (0.1 or 2.0 mg/ L), his cells oxidized I4C-substrates normally (1 1). However, in other vitamin-responsive metabolic disorders, growth in supraphysiologic vitamin concentrations corrects the metabolic defect in cultured cells (10) . Therefore, we cultured cells in subphysiologic riboflavin concentrations ( s 1.4 pg/L; 20) and found that the patient's fibroblasts did not catabolize multiple I4C-substrates as well as did normal cells cultured in the same media or as did his cells cultured in riboflavin-supplemented media. Under these culture conditions, oxidation of [I-I4C]-, [9,10(n)-3H]-, and [ 15,16(n)-3H]palmitates fell dramatically in both control and patient cells. Some aspect of long-chain fatty acid oxidation in fibroblasts seems especially sensitive to riboflavin depletion. Although the available data cannot explain these observations (2 l), these intact cell oxidation assays cannot distinguish between the primary and secondary effects of riboflavin deprivation on palmitate oxidation. Normal [I .4-14C] succinate oxidation in riboflavin-depleted patient cells implied normal function of both succinate dehydrogenase, a FAD-requiring enzyme of the inner mitochondrial membrane, and the main electron transport chain from coenzyme Q to cytochrome ua3 (1, 3, 6, 9, 11). Analogously, liver mitochondria from weanling rats fed a riboflavin-depleted diet showed dramatic decreases in fatty acid oxidation and in ADH activities when compared with rats fed a normal diet; succinate oxidation was much less severely affected (21) . In our experiments, the degree of riboflavin depletion sufficed to unmask the patient's vitamin-responsive defect without uniformly altering acyl-CoA metabolism in control cells. Normal cell survival in our experiments suggested that riboflavin depletion did not affect viability of either patient or controls. Cells from both nonriboflavin-responsive mild MAD patient 840 and MCADH-deficient patient SG (6, 7) oxidized [I-'4C]octanoate identically after culture in media containing s 1.4 pg/L, 0.1 mg/L, and 2.0 mg riboflavin/L (data available upon request). Thus, worsening of the oxidative defect upon riboflavin depletion is not a general phenomenon in cells from patients with P-oxidation defects.
Defects in one of many systems could explain this patient's riboflavin-responsive metabolic disorder: cellular riboflavin uptake, cytosolic FMN/FAD synthesis, mitochondrial FMN/FAD uptake or homeostasis, or FAD binding to ADH. ETF. or ETF:ubiquinone oxidoreductase apoenzymes. Information is available concerning several of these steps (22). Although there is a high-affinity riboflavin-binding protein in the maternal circulation of ovulating birds, there is no known specific intra-or extracellular riboflavin transport protein in mammals (23) . Riboflavin transport into the cell is energy-dependent and involves metabolic trapping of riboflavin as FMN (24). FAD synthesis requires two enzymes located in the cytosol, riboflavin kinase converting riboflavin to FMN and FAD pyrophosphorylase synthesizing FAD from FMN (22, 24) . Currently, the mechanisms of FAD transport into mitochondria and/or maintenance of matrix FAD levels are unknown. FAD is bound ionically to the ADH, ETF, and ETF:ubiquinone oxidoreductase (25, 26).
To study cellular riboflavin uptake and FMN/FAD synthesis, cells were incubated with I4C-riboflavin and I4C-FMN and -FAD levels measured. Total serum flavin concentration is 26-37 pg/L in man, with 18-30 pg/L representing FAD (20) . For these studies, we used a 30-fold range of 14C-riboflavin concentrations. including a subphysiologic level (3 pg/L), because the metabolic defect in intact fibroblasts was most pronounced in cells cultured in riboflavin-depleted medium. We found that whole cell and cystosolic I4C-FMN and -FAD contents were similar in both control and patient cells under all study conditions. Using a different separation system and 60-to 2000-fold higher concentrations of 14C-riboflavin, Gregersen et al.
(1 1) also found normal cellular riboflavin uptake and incorporation into I4C-FMN and -FAD in this patient. Our present results further suggest that deficient cellular riboflavin uptake and synthesis of FMN and FAD are not the primary biochemical defects in this patient.
Uniform labeling of cellular flavin pools with 14C-riboflavin revealed normal kinetics and levels of I4C-flavin accumulations in the patient's cells cultured in physiologic I4C-riboflavin concentrations, which is consistent with the data from the shortterm 14C-radiolabeling experiments. However, the patient's cells did not maintain flavin cofactor pools when normally depleted of riboflavin for an extended period. These observations are consistent with some generalized biochemical defect altering overall cellular flavin cofactor biosynthesis, metabolism, and homeostasis, rather than an isolated defect involving only a single mutant apoflavoenzyme with an altered affinity for FAD. This interpretation is consistent with our data on mitochondrial I4C-FAD contents, MCADH, and ETF activities discussed below.
To measure mitochondrial FAD content, fibroblasts were incubated with 14C-riboflavin. the mitochondria isolated, and I4C-FMN and -FAD contents measured. I4C-FMN contents were 554% of control after culture in low I4C-riboflavin and increased to normal in high I4C-riboflavin. After incubation with low I4C-riboflavin, the patient's I4C-FAD content did not increase from I to 4 h and was 29% of control at 4 h, whereas control mitochondrial I4C-FAD contents rose significantly during the same time interval. After a 4-h incubation with high physiologic levels of 14C-riboflavin (3 1.4 pg/L), the patient's I4C-FAD content rose into the normal range, whereas control I4C-FAD contents did not increase. Thus, control mitochondrial FAD contents apparently attain steady state at even very low extracellular riboflavin concentrations (4.4 crg/L = 12 nM), whereas the patient's cells require much higher extracellular concentrations to reach control FAD levels. These observations are consistent with the vitamin responsiveness of his metabolic block (4, 11) . Inasmuch as we found normal whole cell and cytosolic I4C-FMN and -FAD contents in the patient, this result suggests defective maintenance of mitochondrial FMN and FAD levels in his cells.
We also studied two enzymes of &oxidation for defective FAD binding to altered apoenzymes. MCADH activities in both control and patient cells fell to similar low levels after culture in riboflavin-depleted media: preincubation of these control and patient cell sonic supernatants with FAD did not restore MCADH activity. Several mechanisms could explain loss of apo-MCADH after growth in riboflavin-depleted medium: increased turnover of unstable apo-MCADH without FAD in vivo or loss of apo-MCADH during preparation of cell sonic supernatants.
Hoppel et ul. (27) and Sakurai et ul. (21) found decreased MCADH activities in liver mitochondria from rats fed a riboflavin-deficient diet; the latter authors reconstituted holo-MCADH after incubation of their preparations with FAD, which is consistent with preservation of functional apoenzymes. Goodman (28) found that glutaryl-CoA dehydrogenase activity decreased in riboflavin-deficient rats and was more thermolabile when FAD was absent, suggesting stabilization of the apoenzyme by FAD. Relative destabilization of apo-MCADH in our control cells during riboflavin-deprivation probably leads to apoenzyme loss during cell sonication, obscuring any preferential loss of apo-MCADH in the patient's cells. Culture in riboflavin-depleted media did not lower MCADH activity in either control or patient mitochondrial matrix preparations, supporting this hypothesis.
We found no ETF activity differences between patient or control cell sonic supernatants after culture in riboflavin-depleted medium. We postulated that cell sonication mixed mitochondrial apo-ETF with cytosolic FAD, reconstituted ETF holoenzyme, and obscured any ETF activity reduction caused by reduced mitochondrial FAD content in the patient. This possibility is rendered plausible by our finding mildly reduced mitochondrial matrix ETF activity in riboflavin-depleted patient's cells, which was reversed by FAD addition. Culture in riboflavin-depleted medium should not produce ETF apoenzyme loss per se, inasmuch as Sakurai et 01. (2 I ) found no differences in ETF activity in liver mitochondria from rats fed riboflavin-depleted or -supplemented diets. Because riboflavin depletion apparently lowered the patient's ETF activity more than his MCADH activity and because ETF appears rate-limiting for turnover of all the ADH (1. 7, 8) , decreased ETF activity could help explain his impaired mitochondrial acyl-CoA dehydrogenation (1 1).
Assaying MCADH and ETF in mitochondria from the patient's cells cultured in riboflavin-depleted media did not demonstrate the large activity decreases that might be expected from the observed decreases in cellular and mitochondrial I4C-FAD levels. Our mitochondrial matrix fractions, although purified 10-to 15-fold ( 17) , may contain trace amounts of cytoplasmic FAD, partially reconstituting the active holoenzymes. In contrast, the lack of large activity decreases under these conditions also argues against the existence of mutant MCADH or ETF apoenzymes with greatly decreased FAD affinities. inasmuch as extremely high cofactor concentrations are generally required to restore activity in such circumstances (10) .
We suggest that this patient's riboflavin-responsive MAD phenotype results from a defect in maintaining mitochondrial FAD levels, presumably lowering the overall efficiency of acyl-CoA dehydrogenation and @-oxidation. Our data argue against defects in cytoplasmic FMN and FAD synthesis; other possible explanations include reduced mitochondrial FMN or FAD uptake, intramitochondrial conversion of FMN to FAD, or synthesis and turnover of a mitochondrial flavoprotein essential to maintain mitochondrial FAD levels. Because we postulate that this patient has an inherited disorder involving a single gene product, the last possibility seems unlikely, inasmuch as at least 10 different flavoenzymes are present in the mitochondrial inner membrane and matrix compartments. It seems improbable that only one plays a central role in maintenance of mitochondrial FAD levels. Additional studies of the other possibilities are clearly warranted and are in progress in our laboratory.
